What GHK-Cu is. And where it comes from
GHK-Cu is a naturally occurring copper-binding tripeptide consisting of glycine, histidine, and lysine (Gly-His-Lys). It was first isolated from human plasma albumin by biochemist Loren Pickart in 1973. GHK-Cu is found in plasma, saliva, and urine and declines significantly with age: plasma levels are approximately 200 ng/mL at age 20, dropping to around 80 ng/mL by age 60.
GHK-Cu is one of the few peptides where the compound is endogenous, your body makes it. And the age-related decline is well-documented. Whether that decline is causal in aging or merely correlative is the central question the research is trying to answer.
Mechanism, in plain English
GHK-Cu functions as a matrikine. A signaling peptide derived from or associated with the extracellular matrix (ECM). Its copper-chelating properties are central to its biology:
- ECM remodeling. GHK-Cu activates matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), regulating the balance between ECM breakdown and synthesis. This underlies its wound-healing activity.
- Collagen and elastin synthesis. GHK-Cu upregulates fibroblast production of collagen types I, II, and III, as well as elastin and proteoglycans.
- Antioxidant and anti-inflammatory signaling. GHK-Cu modulates NF-kB pathways and reduces oxidative stress markers in cell culture models.
- Gene expression. Pickart and others have reported that GHK-Cu modulates expression of hundreds of genes in aging-related pathways.
What the evidence shows
Wound healing. Multiple animal studies and some human data support GHK-Cu acceleration of wound closure and tissue repair. A clinical study by Finkley et al. (2003) showed topical GHK-Cu improved skin laxity and density vs vehicle control.
Hair growth. Small studies suggest GHK-Cu may stimulate hair follicle enlargement and reduce hair loss. Evidence is limited and mostly from industry-funded studies.
Anti-aging gene expression. Pickart published analyses suggesting GHK-Cu reverses expression patterns of genes associated with aging in tissue culture models. Human clinical translation of these findings has not been established.
The overall evidence base is strongest for topical wound healing and skin remodeling applications. Systemic anti-aging claims are mechanistically plausible but not established in human RCTs.
FDA status (this month)
GHK-Cu is not FDA-approved as a drug. It is widely used as a cosmetic ingredient in OTC skincare products under FDA cosmetic regulations (which do not require efficacy approval). Injectable or systemic GHK-Cu formulations are used off-label through compounding pharmacies. Last reviewed 2026-08-09.
Common synonyms researchers use
GHK-Cu · Copper peptide · Glycyl-L-histidyl-L-lysine copper · GHK tripeptide · Copper(II) GHK
Safety & adverse-event landscape
Topical GHK-Cu has a well-established safety profile in cosmetic use with few reported adverse effects, mild irritation in sensitive skin types. Systemic safety data from injectable use is limited given no formal clinical trial program. Copper overload is theoretically possible with excessive systemic dosing but has not been reported in the published literature on GHK-Cu. Always consult a qualified healthcare provider.
Frequently asked questions
Want the complete anti-aging and longevity peptide reference?
The Peptexa Top-5 free guide covers the most-studied compounds with the clearest evidence, mechanism, evidence level, and FDA status for each.
What the preclinical evidence shows
The bulk of the published evidence comes from rodent models, tendon transection and Achilles repair, vascular ligation, NSAID-induced gut damage, and fistulizing colitis models. Effects have been reported as positive in tendocyte outgrowth assays, in vascular angiogenesis assays, and in rat colitis models. The most-cited review is Sikiric (2018) in Current Pharmaceutical Design.
Human published data is limited to small case-series reports and registry submissions. There are no large randomized controlled trials to date. The bulk of the discussion in online health communities reflects animal extrapolation, not human-trial data.
Strong preclinical animal research supports investigation into tendon, ligament, and gastrointestinal healing. Human clinical evidence remains limited despite extensive anecdotal use.
FDA status (this month)
BPC-157 is not FDA-approved for any human indication. On July 23-24, 2026, an FDA Pharmacy Compounding Advisory Committee reviewed several peptides including BPC-157 and voted to recommend reviewing whether compounding pharmacies may be allowed to produce them. A rule-making step would be required before any compounding access is granted. And that step is not FDA approval. Coverage: NYT briefing. Last reviewed 2026-08-09.
Common synonyms researchers use
BPC 157 · BPC-157 · Body Protection Compound 157 · PL-14736 (early proprietary designation in the Sikiric et al. literature).
Safety & adverse-event landscape
In the published preclinical literature, BPC-157 has been administered to rodents over short and medium-term protocols without reported mortality. Adverse-event data in humans is limited. The compound's interaction with nitric oxide pharmacology suggests theoretical considerations with vasodilator and cardiovascular medications, consult your provider if you take any.
Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision that involves a peptide, supplement, or therapeutic compound.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The Peptexa Top-5 Free Guide
Five compounds. Mechanism-led. Evidence-ranked. Free PDF, no email required.
Get the Free Guide →